Cingulate Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Hargroves Thomas Jeffrey, was filed 08 Jun 2026.
Cingulate Inc.: what insiders have been doing
This page follows insider dealings at Cingulate Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 15 filings were filed, from 7 insiders.
Only purchases show up on the open market, 5 purchases in all worth €555k, filed by 5 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €413k, bought by Hargroves Thomas Jeffrey and made public on 8 June 2026. The buyers include 3 senior executives, 1 finance chief and 1 chief executive.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 8 June 2026, 154 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 15 filings here. The full history, which starts in 2021, counts 42 purchases against 2 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -22.4 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +0.2%Entry US$4.65 · Close 21 Oct 2026 US$4.66
- -29.1%Entry US$6.57 · Close 21 Oct 2026 US$4.66
- -29.1%Entry US$6.57 · Close 21 Oct 2026 US$4.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 97,276 shares@ US$5.04100.0% of flowCommon StockSEC:0001493152-26-027794:0Canonical exit: 14 May 2026 (T+90)
- 1,828 shares0Common StockSEC:0001493152-26-009723:1
- 1,025 shares0Common StockSEC:0001493152-26-009719:1
- 2,086 shares0Common StockSEC:0001493152-26-009721:1
- 6,427 shares0Common StockSEC:0001493152-26-009720:1
- 2,959 shares0Common StockSEC:0001493152-26-009722:1
- 4,526 shares0Common StockSEC:0001493152-26-009723:0
- 6,862 shares0Common StockSEC:0001493152-26-009722:0
- 5,475 shares0Common StockSEC:0001493152-26-009721:0
- 15,329 shares0Common StockSEC:0001493152-26-009720:0
- 4,526 shares0Common StockSEC:0001493152-26-009719:0
- 19,455 shares@ US$5.047.1% of flowCommon StockSEC:0001493152-26-006027:0Canonical exit: 7 May 2026 (T+90)
- 1,946 shares@ US$5.04100.0% of flowCommon StockSEC:0001493152-26-006024:0Canonical exit: 7 May 2026 (T+90)
- 4,864 shares@ US$5.0433.6% of flowCommon StockSEC:0001493152-26-006026:0Canonical exit: 7 May 2026 (T+90)
- 6,809 shares@ US$5.0472.2% of flowCommon StockSEC:0001493152-26-006025:0Canonical exit: 7 May 2026 (T+90)
- 202 shares@ US$4.16521.1% of flowCommon StockSEC:0001493152-24-033196:0
- 694,096 sharesCommon StockSEC:0001493152-24-014504:1
- 341,912 shares@ US$0.0020.1% of flowCommon StockSEC:0001493152-24-014504:0
- 55 shares@ US$27.103.2% of flowCommon StockSEC:0001493152-24-011034:0Canonical exit: 13 Jun 2022 (T+90)
- 5,000 shares@ US$0.66975.1% of flowCommon StockSEC:0001493152-23-032961:0Canonical exit: 14 Dec 2023 (T+90)
- 1,823,155 shares@ US$0.548577.2% of flowCommon StockSEC:0001493152-23-028563:0Canonical exit: 9 Nov 2023 (T+90)
- 2,000 shares@ US$1.012.8% of flowCommon StockSEC:0001493152-23-017842:1Canonical exit: 13 Aug 2023 (T+90)
- 4,000 shares@ US$1.086.4% of flowCommon StockSEC:0001493152-23-017842:0Canonical exit: 10 Aug 2023 (T+90)
- 10,000 shares@ US$1.016623.7% of flowCommon StockSEC:0001493152-22-035892:0Canonical exit: 16 Mar 2023 (T+90)
- 13,267 shares@ US$1.0123.8% of flowCommon StockSEC:0001493152-22-035633:1Canonical exit: 14 Mar 2023 (T+90)
25 of 57 declarations
About Cingulate Inc.
Cingulate Inc. is a clinical-stage biopharmaceutical company listed on the U.S. NASDAQ market in the United States. For French-speaking investors, it is best understood as a focused CNS-oriented small-cap biotech rather than a diversified pharma platform. The company is centered on attention-deficit/hyperactivity disorder (ADHD) and anxiety-related disorders, using its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop branded next-generation pharmaceutical products designed to provide more consistent coverage over the course of the day and reduce the drawbacks associated with multiple-dose regimens. ([cingulate.com](https://www.cingulate.com/investors?utm_source=openai))
Cingulate’s roots are in Cingulate Therapeutics, and its operational base is in Kansas City, in the United States. That geography matters: the company is built around a Midwestern biotech footprint rather than a large coastal pharmaceutical hub. Its strategy has been to build a small number of differentiated assets around PTR™, with the commercial thesis resting on improved dosing convenience, better duration of action, and stronger intellectual property protection than a simple reformulation story. The company describes itself as a Phase 3 clinical-stage biopharmaceutical company focused on innovative product candidates for ADHD and anxiety-associated disorders. ([cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-therapeutics-announces-expansion-accommodate-growth?utm_source=openai))
Read moreShow less
The lead program is CTx-1301 (dexmethylphenidate HCl), Cingulate’s flagship ADHD candidate. In October 2025, the U.S. FDA accepted the company’s New Drug Application and assigned a PDUFA target action date of May 31, 2026, making regulatory review the central near-term catalyst. In March 2026, the company said it had received a U.S. patent notice of allowance for CTx-1301 and also secured additional European patent grants, which strengthens the IP narrative around the lead asset. Cingulate also appointed Bryan Downey as Chief Commercial Officer in 2025 to prepare for a potential launch, indicating that management is actively building commercial readiness ahead of a possible approval decision. ([cingulate.com](https://www.cingulate.com/news-releases/news-release-details/cingulate-names-industry-veteran-bryan-downey-chief-commercial/?utm_source=openai))
From a competitive standpoint, Cingulate remains a niche player in a market dominated by much larger ADHD franchises. Its opportunity is tied to whether PTR™ can translate into meaningful clinical and commercial differentiation, particularly for patients and prescribers seeking all-day symptom coverage with fewer dosing issues. At the same time, the investment case remains binary and execution-sensitive because the company is still pre-commercial and dependent on regulatory outcomes, supply-chain preparation, and capital access. Recent corporate updates in 2026 show that Cingulate raised $12 million in a private placement and ended the first quarter of 2026 with a stronger cash position, helping fund operations into the next major milestone. For investors, the story is therefore one of high regulatory leverage, IP-driven differentiation, and concentrated product risk on the NASDAQ in the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/cingulate-announces-closing-12-million-private-placement-priced-market-under-nasdaq?utm_source=openai))
